Compare H2O America (HTO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Novo Nordisk A/S — how do they compare? H2O America trades at $63.88 (market cap $2.68B), while Novo Nordisk A/S trades at $48.15 (market cap $218.83B). The key difference: Novo Nordisk A/S is far larger — about 81.7× H2O America's market cap, and Novo Nordisk A/S pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| HTO | NVO | |
|---|---|---|
Market Cap | $2.68B | $218.83B |
Sector | Technology | Health |
52-Week High | $65.43 | $71.70 |
52-Week Low | $44.44 | $35.29 |
Enterprise Value | $4.40B | $237.87B |
Dividend Yield | 2.75% | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $64.52, down 1.39% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported a Q1 2026 EPS beat of $0.50 versus $0.48 expected, with revenue of $816 million in 2026 and a net income margin of 12.86%. A dividend of $0.44 per share is scheduled for payment on June 1, 2026. Analyst consensus is strongly bullish with an 80% buy rating and a $63.50 price target.
The outlook for HTO is positive, supported by steady earnings growth, a reliable dividend, and strong institutional interest. Risks include high capital expenditure demands and sensitivity to regulatory changes in the utilities sector. The stock presents a value opportunity with a P/E of 22.11, trading near analyst targets with potential upside to the high target of $67.00.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
